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The behavior and myelinogenic properties of glial cells have been well documented following transplantation into regions of focal
experimental demyelination in animal models. However, the ability of glial cell preparations to remyelinate in such models does not
necessarily indicate that their transplantation into demyelinated lesions in clinical disease will be successful. One of the precluding factors in
this regard is a greater understanding of the environmental conditions that will support transplant-mediated remyelination. In this study, we
determined whether the complex and reactive CNS environment of the mouse hepatitis virus (MHV) model of multiple sclerosis (MS) could
support transplant-mediated remyelination. Striatal neural precursors derived from postnatal day 1 mice were committed to a glial cell lineage
and labeled. Immunohistochemical staining indicated that this population generated >93% glial cells following differentiation in vitro.
Transplantation of glial-committed progenitor cells into the T8 spinal cord of MHV-infected mice demonstrating complete hindlimb paralysis
resulted in migration of cells up to 12 mm from the implantation site and remyelination of up to 67% of axons. Transplanted-remyelinated
animals contained approximately 2 the number of axons within sampled regions of the ventral and lateral columns as compared to non-
transplanted animals, suggesting that remyelination is associated with axonal sparing. Furthermore, transplantation resulted in behavioral
improvement. This study demonstrates for the first time that transplant-mediated remyelination is possible in the pathogenic environment of
the MHV demyelination model and that it is associated with locomotor improvement.
D 2004 Elsevier Inc. All rights reserved.Keywords: Stem cell; Oligodendrocyte; Remyelination; MHV; Multiple sclerosis; Glia; Demyelination
Introduction et al., 1985; Rodriguez et al., 1987; Sasaki and Ide, 1989;Remyelination is a successful regenerative event within
the adult central nervous system (CNS), as it can restore
saltatory conduction (Smith et al., 1979) and facilitate
functional recovery (Jeffery and Blakemore, 1997). Remye-
lination has been demonstrated in a variety of experimental
demyelination/mutant models (Blakemore, 1973, 1974,
1975, 1982; Duncan et al., 1988; Gumpel et al., 1989;
Herndon et al., 1977; Jeffery and Blakemore, 1995, 1997;
Jeffery et al., 1999; Keirstead and Blakemore, 1999; Moore0014-4886/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.expneurol.2004.01.028
* Corresponding author. Fax: +1-949-824-9272.
E-mail address: hansk@uci.edu (H.S. Keirstead).
URL: http://www.reeve.uci.edu/.Yajima and Suzuki, 1979) and occurs spontaneously in
naturally occurring demyelinating diseases such as MS
(Prineas et al., 1993a). However, remyelination failure is
more prevalent than its success when considering the
spectrum of pathologies that affect the CNS. Although
remyelination is usually successful in most animal models,
it is often incomplete in the Theiler’s model of demyelin-
ation (Murray et al., 2001). Furthermore, remyelination is
less efficient in old animals than in young animals (Shields
et al., 1999). The failure of remyelination is illustrated
within foci of chronic demyelination within the later stages
of MS (Prineas et al., 1993b). Chronic MS lesions are
characterized by oligodendrocyte loss (Ozawa et al.,
1994), with remyelination limited to the borders of inactive
plaques (Suzuki et al., 1969).
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ical deterioration. In addition to restoring normal impulse
conduction (Utzschneider et al., 1994), remyelination may
decrease axonal degeneration/transection. This is suggested
by the demonstration that chronically demyelinated axons
are vulnerable to degeneration/transection and that axonal
loss in the later stages MS contributes to clinical deteriora-
tion (Bjartmar et al., 1999; De Stefano et al., 1998; Trapp et
al., 1998). These findings underscore the importance of
developing therapeutic strategies to enhance remyelination.
One approach is to activate or enhance the response of
endogenous mechanisms for repair, as has been demonstrat-
ed following growth factor administration in the experimen-
tal autoimmune encephalomyelitis (EAE) demyelination
model (Yao et al., 1995), or passive transfer of antiserum
(Rodriguez et al., 1987) or purified immunoglobulin (Rodri-
guez and Lennon, 1990) from mice immunized with spinal
cord homogenate into the Theiler’s demyelination model
(Miller and Rodriguez, 1995). An alternative approach to
remyelinating areas of demyelination is the transplantation
of remyelination-competent cells.
Stem cells and neural precursors represent attractive
sources for the generation of remyelination-competent cells,
as they can be readily amplified and differentiated to the
oligodendrocyte lineage (Ben-Hur et al., 1998; Brustle et al.,
1999). Stem cell-derived glial precursors have been shown
to myelinate following transplantation into the myelin-
deficient rat (Brustle et al., 1999), and neural precursor-
derived glial-committed progenitors (Ben-Hur et al., 1998;
Keirstead et al., 1999) have been shown to myelinate
following transplantation into regions of acute experimental
demyelination (Keirstead et al., 1999). More recently, intra-
cerebroventricular or intrathecal implantation of neural
precursors into the EAE demyelination model resulted in
migration of transplanted cells into white matter and their
differentiation to astrocytes and oligodendrocytes, although
no assessment of their ability to myelinate was performed
(Ben-Hur et al., 2003). To determine whether transplanta-
tion represents a viable strategy for treating demyelination,
it is necessary to better understand the range of environ-
mental conditions that support transplantation-mediated
remyelination.
In this study, we investigated the ability of the
complex and reactive disease state of the chronic demy-
elinating MHV model of MS to support transplant-medi-
ated remyelination. Intracerebral injection of the J2.2v-1
strain of MHV results in acute encephalomyelitis with
demyelination, followed 10–12 days later by an immune-
mediated demyelinating encephalomyelitis with hindlimb
paralysis and progressive CNS destruction, including the
initiation of new demyelination foci probably for the life
of the mouse (Fleming et al., 1987; Haring and Perlman,
2001; Lane et al., 1998; Stohlman and Hinton, 2001;
Stohlman et al., 2002). This model provides an environ-
ment of ongoing demyelinating pathogenesis, and is thus
distinct from gliotoxin lesions. Intraspinal transplantationof glial-committed progenitors into the MHV model of
MS resulted in extensive migration of transplanted cells,
robust remyelination, axonal sparing, and behavioral im-
provement. These results show that transplant-mediated
remyelination is possible following intraspinal transplan-
tation into an environment of ongoing pathogenesis
resembling MS.Material and methods
Cell culture
Striata from 4 postnatal day 1 C57BL/6 mice were
dissected, triturated, and maintained as previously de-
scribed (Ben-Hur et al., 1998). Trypan blue was used to
determine cell viability. Cells were grown for 5 days as
floating clusters in 6-well low-adherent plastic dishes
(Corning Life Sciences Acton, MA) at an initial density
of 2  106 cells/5 ml of DMEM:F12, B27 supplement
(Gibco-Invitrogen, Carlsbad, CA) with insulin, sodium
selenite, transferrin, putrescin, progesterone, T3, detailed
in Ben-Hur et al. (1998), and 0.02 Ag/ml epidermal growth
factor (EGF; Sigma-Aldrich, St. Louis, MO). On day 2,
culture supernatant containing the floating clusters was
removed and centrifuged at 400 g for 5 min. Clusters
were then resuspended in fresh media and added to new
culture dishes. On day 3, 0.02 Ag/ml EGF was added to the
culture dishes. On day 4, clusters were washed, resus-
pended in fresh media, and added to new culture dishes.
On day 5, clusters were incubated with 10 mM BrdU
(Sigma-Aldrich) in the culture medium overnight. One
culture dish was not labeled with BrdU to compare viability
and differentiation in the presence and absence of BrdU.
On day 6, cultures were prepared for transplantation.
Clusters were dissociated with 0.05% Trypsin-EDTA (Invi-
trogen Canada Inc., Burlington, ON) for 5 min, triturated,
centrifuged for 5 min at 400  g, resuspended three times
in calcium- and magnesium-free DMEM (Gibco-Invitro-
gen), and concentrated to a final density of 12  104 cells/
Al in the same media. The cell preparation was kept on ice
for a maximum of 1 h before transplantation. On the day of
transplantation, some cells were prepared for immunocyto-
chemistry. Clusters were centrifuged for 5 min at 400  g
and resuspended three times in fresh media without EGF,
and were plated on 10 mg/ml poly-L-lysine (Sigma-
Aldrich) and 15 Ag/ml laminin (Sigma-Aldrich) coated four
chamber, imaging slides (Nalgene-Nunc International,
Rochester, NY).
Immunocytochemistry
To assess differentiation potential, cells were grown on
imaging slides on adherent substrate for 7 days, then fixed
in 4% paraformaldehyde (Fisher Scientific, Pittsburgh, PA)
in PBS for 10 min and immunocytochemical staining was
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were blocked with 20% normal goat serum (NGS) (Chem-
icon, Temecula, CA) for 30 min at room temperature.
Primary antibodies (polyclonal rabbit anti-GalC, Chemi-
con, 1:200 dilution in 4% NGS; monoclonal mouse anti-
NeuN, Chemicon, 1:200 dilution in 10% NGS; polyclonal
rabbit anti-GFAP, DAKO, Denmark, 1:200 dilution in 4%
NGS; monoclonal mouse anti-CD 11 b, Serotec, UK,
1:200 dilution in 4% NGS; polyclonal rat anti-BrdU,
Accurate Chemical and Scientific Corporation, Westbury,
NY, 1:200 dilution in 4% NGS) were applied to imaging
chambers overnight at 4jC. Imaging chambers were rinsed
three times with PBS, incubated for 30 min in 4% NGS,
and fluorescent-conjugated secondary antibodies (Alexa
488 or 594, goat anti-rabbit, goat anti-rat, or goat anti-
mouse IgG H+L, 1:200 dilution in 4% NGS; Vector
Laboratories, Burlingame, CA) was applied and incubated
for 1 h at room temperature. Chambers were rinsed three
times in PBS, and nuclear staining was conducted by
exposing cultures to bis-benzimide (Hoechst 33258, Mo-
lecular Probes, Eugene, OR) for 10 min. Cell quantifica-
tion was conducted using an Olympus AX-80 light
microscope with a 20 objective. The percentage of
immunopositive cells was determined by dividing the total
number of immunopositive cells by the total number of
Hoechst-positive cells in each imaging chamber, and
averaging the results from three different imaging cham-
bers per marker. A total of 1940 Hoechst-positive cells
were counted for these analyses. Each 4-chamber imaging
slide had one no-primary control chamber and three
stained chambers for each of the markers mentioned
above. Only immunopositive cells with clearly Hoechst-
positive nucleus were counted.
MHV model
Age-matched, weight-matched (20–22 g) male C57BL/
6 mice (H-2b background; National Cancer Institute,
Bethesda, MD; n = 16) were anesthetized by methoxyflu-
rane inhalation (Pitman-Moore Inc., Washington Crossing,
NJ). Mice received intracerebral injections of 500 plaque
forming units of the neurotropic corona virus MHV strain
J2.2v-1 (kindly provided by J. Fleming, University of
Wisconsin, Madison, WI), suspended in 30 Al of sterile
saline (Lane et al., 1998). Intracerebral injection of MHV
results in a biphasic disease: acute encephalomyelitis with
myelin loss, followed 10–12 days later by an immune-
mediated demyelinating encephalomyelitis with hindlimb
paralysis and progressive destruction of the CNS (Fleming
et al., 1987; Haring and Perlman, 2001; Lane et al., 1998;
Stohlman et al., 2002). Two of the MHV injected animals
died during the first week post injection; there is an 80–
90% survival rate of animals injected with this viral strain,
and the animals usually die during the first 12 days of
acute infection. If the animals survive the acute stage of
disease there is >95% chance of survival. Control (sham)animals (n = 8) were injected with 30 Al of sterile saline
alone and did not develop any behavioral or histological
deficits.
Transplantation
Twelve days after MHV intracerebral injection, each
animal (n = 7) received a single injection of 240,000 cells
in 2 Al of calcium- and magnesium-free DMEM (Gibco-
Invitrogen) at T8 of the spinal cord, using the protocol
described in Blakemore and Crang (1992). Briefly, ani-
mals were anesthetized with Avertin and received a
laminectomy at T8. The spinal process cranial to the
laminectomy was immobilized using a micromanipulator
and the transplant needle, a 10-Al Hamilton syringe
(Hamilton Company, Reno, NV) with a silicon-coated
pulled glass tip, was lowered into the spinal cord using
a stereotactic manipulator arm. Cell suspensions were
injected into one site at the midline of the spinal cord.
The needle was removed from the cord 5 min after
injection of the cells was complete. In addition, six control
animals that received an MHV intracerebral injection
received no transplant. One animal died during transplan-
tation/anesthesia. Animals were randomly selected for
inclusion in either group and all received an incision to
the skin overlying T8 to allow blinded analyses for the
duration of the experiment.
Behavioral testing
Behavioral testing of all animals was conducted by a
blinded observer, every other day using the 4-point
clinical scoring scale (Houtman and Fleming, 1996)
where 0 = normal, 1 = limp tail, 2 = waddling gait
and partial hindlimb weakness, 3 = complete hindlimb
paralysis, 4 = death animal. This 4-point scale was
supplemented with a single increment between each point,
such that 1.5 = limp tail and partial waddling gait and no
hindlimb weakness, 2.5 = hindlimb weakness and partial
hindlimb paralysis, 3.5 = complete hindlimb paralysis and
moribund disposition. Animals were acclimated and be-
haviorally tested 1 day before MHV injection. After MHV
injection, animals were tested every day. After transplan-
tation, animals were tested every other day for 2 weeks
and then every 3rd day until the end of the experiment.
Statistical significance was determined using the Mann–
Whitney U test.
Histology
Animals were euthanized under chloral hydrate anesthe-
sia (Fisher Scientific) 21 days following transplantation or
33 days after MHV infection and fixed by cardiac perfusion
with 4% paraformaldehyde (Fisher Scientific) in 0.1 M
PBS, pH 7.4. The length of spinal cord extending 12 mm
cranial and 10 mm caudal to the site of implantation was cut
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the craniocaudal sequence and orientation. Alternating tis-
sue blocks were processed for resin and cryostat sectioning
and analyzed in a blinded fashion. Resin sections were used
to determine the area of the ventral and lateral columns, and
the number of demyelinated, remyelinated, and normally
myelinated axons. Cryostat sections were used to determine
spread of BrdU-prelabeled transplanted cells and their
differentiation profile.
For resin sectioning, odd numbered blocks were post
fixed in 4% glutaraldehyde (Fisher Scientific), then exposed
to 1% OsO4 (Electron Microscopy Sciences, Fort Washing-
ton, PA), dehydrated in ascending alcohols, and embedded
in Spurr resin (Electron Microscopy Sciences) according to
standard protocols. Transverse semi-thin (1 Am) sections
were cut from the cranial face of each block, stained with
alkaline toluidine blue, cover slipped, and examined by light
microscopy on an Olympus AX-80 microscope using
OLYMPUS MicroSuite B3SV software. Total areas of the
ventral and lateral columns were measured with the 4
objective and averaged. A t test was performed to compare
the areas of the ventral and lateral columns in transplanted
and non-transplanted animals. The state of myelination was
determined by assessing the thickness of the myelin sheath
in relation to the axon diameter (Guy et al., 1989; Hilde-
brand and Hahn, 1978). Demyelinated, remyelinated, and
normally myelinated axons were counted within 4  3750
Am2 areas, totaling 15000 Am2, on each tissue section using
the 100 objective with 2 optical zoom. 15000 Am2
represents approximately 10% of the total area of remyeli-
nation within transplanted animals, which was determined
by measuring the total area of remyelination in tissue
sections from each block in each animal using the 40
objective, and averaging areas from all animals in each
group. These quantitative assessments were conducted
throughout the region extending 8 mm cranial and 6 mm
caudal to the implantation site. The number of demyelinated
axons, remyelinated axons, the total number of axons
(normally myelinated plus demyelinated plus remyelinated
axons), and the percentage of remyelinated axons (number
remyelinated/number total axons) were determined for each
of the four regions on each tissue block, averaged, then
averaged across animals within each group for each tissue
block. A t test was performed to compare these values for
transplanted and non-transplanted groups. To determine
whether the number of remyelinated axons in each animal
correlated with the total number of axons in each counting
area, remyelinated and total axons counts were each aver-
aged among all four counting areas for all blocks for each
animal, and the correlation coefficient between these two
values was determined for both transplanted and non-trans-
planted groups. Statistical analyses were conducted using
SPSS software.
For cryostat sectioning, even numbered blocks were
cryoprotected in 30% sucrose solution in PBS, embedded
in OCT (Fisher Scientific) and frozen sectioned in thetransverse plane at 20 Am on a JUNG CM3000 Leica
cryostat for anti-BrdU staining. For BrdU staining, sections
were washed in PBS, exposed to 50% formamide (Sigma-
Aldrich) and 2N hydrochloric acid (Fisher Scientific) for 30
min at 37jC for DNA denaturation, followed by a 30-min
exposure to 0.3% H2O2 in PBS, then incubated overnight at
room temperature with rat anti-BrdU polyclonal antibody
(Accurate Chemical and Scientific Corporation) at a 1:200
dilution in 4% NGS. Secondary antibody was biotinylated
goat anti-rat heavy and light chain IgG (Sigma-Aldrich).
Vectastain ABC (Vector Laboratories) and 3,3V-diamino-
benzidine (Vector Laboratories) were used for signal visu-
alization. The number of BrdU-positive cells was counted
on three sections 80-Am apart from each tissue block for
each animal using OLYMPUS MicroSuite B3SV software,
and averaged. The numbers of BrdU-positive cells within
corresponding blocks from animals within a group were
then averaged. For BrdU, APC-CC1 double staining, sec-
tions were washed in PBS, exposed to 2N hydrochloric
acid (Fisher Scientific) for 30 min at 37jC for DNA
denaturation, and primary antibodies (rat anti-BrdU,
1:200, Accurate Chemical and Scientific Corporation;
mouse anti-APC-CC1, 1:20, Oncogene Research Products,
San Diego, CA) were diluted in 2% bovine serum albumin
and applied to slides overnight at room temperature. Slides
were rinsed three times with PBS, incubated for 30 min in
2% bovine serum albumin, and secondary antibodies
(Alexa 488 or 594, goat anti-rat or goat anti-mouse IgG
H+L, 1:200 dilution in 2% bovine serum albumin; Vector
Laboratories) were applied and incubated for 1 h at room
temperature.Results
In vitro differentiation of striatal cultures
Trypan blue analysis indicated that approximately 1.1–
1.2  106 viable cells were obtained from each postnatal
day 1 mouse. Floating cell clusters reached approximately
200 Am in diameter after 6 days of culture (Fig. 1a). On day
6, clusters were either (1) dissociated and transplanted into
animals or (2) transferred to an adherent substrate in the
absence of growth factors, grown for an additional 7 days
and assayed for differentiation potential.
As early as 6 h after transfer of cell clusters to an
adherent substrate and concomitant growth factor withdraw-
al, cells started to spread out from the adherent clusters and
by 1 day, displayed complex cellular morphologies (Fig.
1b). After 7 days of growth on adherent substrate, oligoden-
drocytes and astrocytes could be identified by their mor-
phology and immunolabeling. Oligodendrocytes displayed a
multipolar morphology with membranous extensions and
GalC immunoreactivity (Fig. 1c), whereas astrocytes dis-
played a flat or stellate morphology and GFAP immunore-
activity (Fig. 1d). Few NeuN immunoreactive neurons (Fig.
M.O. Totoiu et al. / Experimental Neurology 187 (2004) 254–2652581e) and CD11b immunoreactive microglia (results not
shown) were detected. No-primary antibody control staining
chambers had no positive staining. Different cell types often
occupied discrete regions of the culture dishes. A total of
1940 Hoechst-positive cells were counted for the following
analyses. Quantification of immunolabeled cells indicated
that 85 F 10.7% (range = 64–96, median = 80) of the total
cell population was BrdU immunoreactive following an
overnight pulse (Fig. 1f), and that the differentiation proto-
col yielded 67.4 F 4.4% oligodendrocytes (range = 60–72,
median = 66), 26 F 7.4% astrocytes (range = 20–40,
median = 30) and 6.6 F 6.2% other cell types (range =
1–13, median = 7), which included NeuN + neurons,
CD11b + microglia, and other Hoechst-positive cells notidentified by the immunostains tested (Fig. 1g). No differ-
ence was observed in the viability or differentiation of
BrdU-labeled or -unlabeled cells.
Histological outcome of glial-committed progenitor
transplantation
Transplanted glial-committed progenitors, labeled with
BrdU before implantation, survived and colonized long
lengths of the spinal cord during the 21-day survival period
(Fig. 2), and differentiated into mature oligodendrocytes
(Fig. 3). BrdU-labeled cells were detected 12 mm cranial
and 10 mm caudal to the site of implantation (the extent of
tissue examined), and extended throughout the transverse
plane of the spinal cord, primarily within white matter tracts.
The number of BrdU-labeled cells was greatest around the
site of implantation, and fell off sharply 4–6 mm either side
of the site of implantation. BrdU-labeled cells were absent
in non-transplanted animals (Fig. 2c) and in no-primary
antibody control stains of transplanted animals.
Non-transplanted animals infected with MHV develop a
demyelinating disease accompanied by mononuclear cell
infiltration, widespread myelin destruction, and progressive
degeneration of the CNS in the survivors (Fleming et al.,
1987; Haring and Perlman, 2001; Liu et al., 2001; Stohlman
et al., 2002). Systematic random analyses (Fig. 4a) indicated
that numerous demyelinated axons were present (Figs. 4b, e,
g) among vacuoles, myelin debris, activated macrophages,
lymphocytes, and necrotic cells throughout the region of
spinal cord examined, indicative of ongoing pathogenesis.
The number of demyelinated axons was not significantly
different (P > 0.05) in transplanted and non-transplanted
animals (Fig. 5a), likely because MHV is an ongoing
demyelinating disease generating a similar number of newly
demyelinated axons in both non-transplanted and trans-
planted animals. The number (Fig. 5b) and percentageFig. 1. The differentiation potential of striatal neural precursors can be
restricted by culture conditions. (a) Cell cluster after 5 days of growth in
non-adherent growth factor containing media, viewed in phase contrast.
Cells were grown as free-floating clusters, reaching approximately 200 Am
in diameter. (b) Hematoxylin–eosin-stained cell cluster 1 day after transfer
to an adherent substrate. Cells spread out from clusters within 6 h of plating,
and by 1 day, possess complex morphologies. (c) Multipolar GalC-positive
(green) oligodendrocytes were abundant after 7 days of growth on adherent
substrate in the absence of growth factors (Hoechst-positive nuclei are
blue). (d) GFAP-positive (green) astrocytes were also abundant after 7 days
of growth on adherent substrate in the absence of growth factors (Hoechst-
positive nuclei are blue). (e) Few NeuN-positive (red) neurons were present
(Hoechst-positive nuclei are blue). (f) The majority of cells (85 F 10.7%)
within cultures were BrdU-positive. This field illustrates BrdU-positive
(red) GFAP-positive (green) astrocytes. (g) Quantification of cell types after
7 days of growth on adherent substrate in the absence of growth factors
indicated that the differentiation protocol yielded 67.4 F 4.4% oligoden-
drocytes, 26 F 7.4% astrocytes, and 6.6 F 6.2% other cell types, which
included NeuN+ neurons, CD11b + microglia, and other Hoechst-positive
cells not identified by the immunostains tested. Error bars represent
standard deviation. 40 magnification for a and b, 100 for magnification
for c and d, 400 magnification for e, 200 magnification for f.
Fig. 2. Transplanted glial-committed progenitor cells survived and migrated during the 21-day survival period. (a): BrdU-stained transverse section of the
spinal cord from a MHV-infected mouse 21 days following cell transplantation, 4 mm cranial to the site of implantation. BrdU-positive cells are abundant
within the white matter tracts. Box is magnified in b. (b) BrdU-positive cells are evenly distributed within the lateral white matter tracts. (c) BrdU-stained
transverse section of the spinal cord from a non-transplanted, MHV injected mouse 33 days following MHV injection. Note the absence of BrdU-labeled
cells. (d) Distribution of BrdU-positive cells cranial and caudal to the site of implantation. Error bars represent standard deviation. 100 magnification for
a, 400 magnification for b and c.
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was significantly lower (P < 0.01) than in transplanted
animals, and composed less than 10% of the total number of
axons counted (Fig. 5c). Normally myelinated axons were
exceedingly rare at this time point. Control animals injectedFig. 3. Transplanted glial-committed progenitor cells differentiated into oligoden
stains for BrdU to identify transplanted cells and APC-CC1 to identify mature olig
MHV-infected mouse 21 days following cell transplantation, 1 mm caudal to the sit
in a. (c) Overlay of a and b. Arrows indicate double-labeled BrdU and APC
oligodendrocytes. Arrowheads indicate BrdU+ CC1 cells, illustrating transplan
BrdU, CC1+ cells, illustrating endogenous oligodendrocytes. 600 magnificatiwith saline only did not develop clinical or histopathological
deficit.
Transplantation of glial-committed progenitors resulted
in widespread remyelination (Figs. 4 and 5). Remyelinated
axons were identified by their characteristically thin my-drocytes during the 21-day survival period. Double immunohistochemical
odendrocytes. (a) BrdU-stained transverse section of the spinal cord from a
e of implantation. (b) APC-CC1 immunostaining of the same section shown
-CC1 cells, illustrating that transplanted cells differentiated into mature
ted cells that differentiated into other cell types. Arrow profiles indicate
on.
M.O. Totoiu et al. / Experimental Neurology 187 (2004) 254–265260elin sheaths (Figs. 4c, f, h) and appeared in aggregates
distributed throughout the dorsal, ventral, and lateral
columns among demyelinated axons. Remyelination ex-
tended 12 mm cranial and 10 mm caudal to the implan-
tation site in six of seven transplanted animals. Counts of
remyelinated axons throughout the region extending 8 mm
cranial and 6 mm caudal to the implantation site (the
extent of our quantification; Fig. 5b) indicated that regions
of remyelination contained 54% to 67% remyelinatedaxons (Fig. 5c). Normally myelinated axons were exceed-
ingly rare at this time point; note that for each tissue
block, the number of remyelinated axons (Fig. 5b) plus the
number of demyelinated axons (Fig. 5a) approximates the
total number of axons (Fig. 5d). One transplanted animal
contained few remyelinated axons, similar to non-trans-
planted animals (P > 0.1); immunohistological analysis of
this animal revealed that it contained no BrdU-positive
cells. We did not observe tumor, teratoma, or non-neuronal
tissue formation in transplant recipients, nor did we
observe a qualitative difference in Schwann cell presence
or remyelination between transplanted and non-trans-
planted animals.
Counts of the total number of axons (normally myelin-
ated, demyelinated, and remyelinated) within the region
extending 8 mm cranial and 6 mm caudal to the transplan-
tation site (the extent of spinal cord examined) suggest that
transplanted animals had significantly more axons (P <
0.01) within the ventral and lateral columns as compared to
non-transplanted animals (Figs. 4g, h and 5d). Area meas-
urements of the ventral and lateral columns revealed no
significant difference between animals within and between
the transplanted and non-transplanted groups (P > 0.05, t
test), however, a two-sample t test power analysis indicated
that an experimental n of 6 per group was insufficient to
conclude statistical significance of the differences between
the groups. Nonetheless, these data suggest that the higher
number of total axons within transplanted animals was not a
result of tissue shrinkage in the transplanted animals.Fig. 4. Transplantation of glial-committed progenitor cells resulted in
remyelination. (a) Toluidine blue-stained transverse section of a spinal cord
from a transplanted animal showing the areas from which photographs and
counts were taken. (b) Toluidine blue-stained transverse section of spinal
cord white matter from an MHV-infected mouse 33 days after induction of
disease illustrating the predominance of demyelinated axons (arrow). (c)
Toluidine blue-stained transverse section of spinal cord white matter from an
MHV-infected mouse 33 days after induction of disease and 21 days after
transplantation of glial-committed progenitor cells. Note that the vast
majority of axons bear thin myelin sheaths (arrow) characteristic of
remyelination. (d) Toluidine blue-stained transverse section of spinal cord
white matter from a normal mouse, indicating normal myelin sheath
thickness (arrow), for comparison with panel c. (e) Electron photomicro-
graph of spinal cord white matter from an MHV-infected mouse 33 days
after induction of disease illustrating a demyelinated axon (arrow) and a
normally myelinated axon (arrowhead). (f) Electron photomicrograph of
spinal cord white matter from an MHV-infected mouse 33 days after
induction of disease and 21 days after transplantation of glial-committed
progenitor cells. Note the thin myelin sheaths (arrow) characteristic of
remyelination (for comparison, note the thickness of the normal myelin
sheath in e (arrowhead). (g) Toluidine blue-stained transverse section of
spinal cord white matter from an MHV-infected mouse 33 days after
induction of disease illustrating the predominance of demyelinated axons
amongst vacuoles, macrophages, lymphocytes, and an enlarged extracellular
space. (h) Toluidine blue-stained transverse section of spinal cord white
matter from an MHV-infected mouse 33 days after induction of disease and
21 days after transplantation of glial-committed progenitor cells. Note the
higher proportion of remyelinated axons and total axon density as compared
to non-transplanted animals (g). 40 magnification for a, 2000X for b–d,
39000 for e and f, 800 magnification for g and h.
Fig. 5. Transplantation of glial-committed progenitor cells resulted in remyelination and axonal sparing. (a) Demyelinated axons were present in transplanted
and non-transplanted animals; their numbers within 15000 Am2 of white matter were not statistically different ( P > 0.05). (b) Remyelination extended 8 mm
cranial and 6 mm caudal to the implantation site (arrow) in transplanted animals (the extent of tissue examined) and was significantly greater than the degree of
remyelination in non-transplanted animals at every point examined ( P < 0.01). (c) Throughout this region, 54% to 67% of the total number of axons in the
ventral and lateral columns of transplanted animals were remyelinated. Remyelination in non-transplanted animals was significantly less at every point
examined ( P < 0.01). (d) The total number of axons within 15000 Am2 of white matter in transplanted animals was approximately 2 the total number of
axons within similar regions in non-transplanted animals ( P < 0.01 for all points), suggesting that remyelination is associated with axonal sparing. Error bars
represent standard deviation.
Fig. 6. Transplantation of glial-committed progenitor cells resulted in an
improvement in locomotor abilities. Transplanted animals demonstrated a
significant improvement ( P < 0.01) in locomotor abilities beginning 14
days after transplantation (arrow). From 24 days after induction of disease,
transplanted animals walked with a waddling gait and partial hindlimb
weakness, whereas non-transplanted animals demonstrated complete
hindlimb paralysis. Error bars represent standard deviation.
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of remyelinated axons for each animal within the trans-
planted group indicated a statistically significant correlation
between these two values (r = 0.953; P < 0.05), indicating
that a greater degree of axonal sparing correlated with a
greater degree of remyelination.
Behavioral outcome of glial-committed progenitor
transplantation
All transplanted animals survived for the duration of the
experiment. Non-transplanted animals developed clinical
disease typically characterized by a waddling gait and
partial hindlimb weakness by 8–9 days post-infection,
which progressed to complete hindlimb paralysis by 10
days post-infection, persisting for the duration of the exper-
iment (Fig. 6). Control saline-injected animals displayed
normal locomotor behavior throughout the duration of the
experiment (all animals scored 0).
Transplantation of glial-committed progenitors resulted
in a significant improvement in locomotor abilities (Fig. 6).
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the time of transplantation. Six of seven transplanted ani-
mals demonstrated a significant (P < 0.01) improvement in
locomotor abilities beginning 14 days after transplantation,
which progressed to weight-supported waddling locomotion
with partial hindlimb weakness. One transplanted animal
demonstrated no improvement in locomotor abilities; post-
mortem analysis of this animal revealed that it contained no
BrdU-positive transplanted cells and a degree of remyeli-
nation that was not significantly different (P > 0.1) from
non-transplanted animals.Discussion
Cell replacement strategies must contend with the fact
that the differentiation of transplanted cells is strongly
influenced by the environmental signals and cellular defi-
ciencies operating at the site of implantation. For example,
stem cells isolated from the adult hippocampus generate
new hippocampal neurons and glia following transplanta-
tion into the hippocampi of other animals, while these same
cells generate olfactory bulb neurons expressing appropriate
neurotransmitter phenotypes following transplantation into
the rostral migratory stream, or glial cells following trans-
plantation into regions of the CNS which do not normally
generate neurons in the adult (Gage et al., 1995; Suhonen et
al., 1996). These influences present formidable challenges
to cell replacement strategies aimed at promoting repair of
neurodegenerative disease or injury due to the complex and
reactive environment of such lesions, and point towards
lineage commitment of multipotent cells before transplan-
tation (Keirstead, 2001).
Our differentiation protocol resulted in the generation of
oligodendrocytes and astrocytes in high yield (67.4% and
26%, respectively) from postnatal day 1 derived striatal
neural precursors (Fig. 1), supporting previous studies using
a similar differentiation protocol (Ben-Hur et al., 1998).
Cellular migration in vitro was evident as early as 6 h, and
cellular differentiation in vitro was evident as early as 1 day,
after transfer of cell clusters to an adherent substrate and
concomitant growth factor withdrawal.
To assess migration and differentiation in vivo, undif-
ferentiated prelabeled glial-committed progenitors were
transplanted into regions of demyelination in the MHV
model of MS. Intracerebral injection of the J2.2v-1 strain of
MHV results in initial viral replication in the ependymal
cells lining the ventricles, which subsequently extends to
the central canal, gray and white matter of the spinal cord.
Infectious virus is usually eliminated by days 12–14 post
infection, but is not completely cleared. Acute encephalo-
myelitis with myelin loss is present by day 5 and extends
rapidly in the anterior funiculi. An immune-mediated de-
myelinating encephalomyelitis with hindlimb paralysis and
progressive destruction of the CNS then follows; although
some remyelination takes place, the initiation of new foci ofdemyelination likely continues for the entire life of the
mouse (Fleming et al., 1987; Haring and Perlman, 2001;
Lane et al., 1998; Liu et al., 2001; Stohlman and Hinton,
2001; Stohlman et al., 2002). In the current study, undif-
ferentiated glial-committed progenitors were transplanted
into the thoracic spinal cords of mice with fulminate
demyelinating pathology and complete hindlimb paralysis
as a result of MHV infection. Transplanted cells survived
for the duration of the 21-day post-transplantation period
and spread throughout the mediolateral extent of the spinal
cord as well as 12 mm cranial and 10 mm caudal to the site
of implantation, the extent of the tissue being examined
(Fig. 2). These findings demonstrate that transplanted
progenitor cells are capable of extensive migration through-
out regions of ongoing pathogenesis. Survival and exten-
sive migration of transplanted gliogenic cell populations
has been demonstrated in the developing normal CNS
(Jacque et al., 1992), myelin-deficient mutant CNS (Brustle
et al., 1999; Gansmuller et al., 1991; Liu et al., 2000;
Tontsch et al., 1994), chemically demyelinated CNS
(Groves et al., 1993; Keirstead and Blakemore, 1999),
and in inflamed white matter tracts in the EAE model of
MS (Ben-Hur et al., 2003; Pluchino et al., 2003). However,
the ability of gliogenic cell populations to survive and
migrate in these environments does not indicate that they
will do so in the intact normal adult CNS. When glial
progenitors (Franklin et al., 1996; O’Leary and Blakemore,
1997) are transplanted into the intact normal adult CNS,
they fail to survive or migrate; only when the cells are
placed in the immediate vicinity of active regions of
demyelination, where survival factors are elevated (Hinks
and Franklin, 1999), do they enter the lesion. These find-
ings suggest that the survival and extensive migration of
cells in our study was due in part to the continuity of
pathology throughout the region of migration.
Transplantation of glial-committed progenitors resulted
in extensive remyelination, ranging from 54% to 67% of the
axons present within randomly selected regions of the spinal
cord (Figs. 4 and 5). The in vitro (Fig. 1) and in vivo (Fig. 3)
differentiation profile of these cells, the presence of exten-
sive remyelination only in transplanted animals (Figs. 5b, c),
and the presence of remyelination throughout the region
over which transplanted cells migrated (Figs. 2d and 5b)
suggest that remyelination was conducted by the trans-
planted cell population. Nonetheless, we cannot rule out
the possibility that remyelination in transplanted animals
was carried out by endogenous cells that may have been
activated as a result of trophic support by the transplanted
population.
Cumulative axonal loss has recently been demonstrated
in several human (Bitsch et al., 2000; Ferguson et al., 1997;
Trapp et al., 1998) and rodent (Bjartmar et al., 1999;
Griffiths et al., 1998; Yin et al., 1998) demyelinating
pathologies, using in vivo magnetic resonance imaging
(Stevenson and Miller, 1999; Van Waesberghe et al.,
1999), in vivo magnetic resonance spectroscopy (Arnold
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of brain sections (Ferguson et al., 1997; Trapp et al., 1998),
and biochemical methods (Bjartmar et al., 2000). Chronic
demyelination is a probable cause of such axonal loss
(Bjartmar and Trapp, 2001). To determine whether remyeli-
nation was associated with axonal sparing in the current
study, total axon numbers were determined within the
ventral and lateral columns of transplanted and non-trans-
planted animal groups 33 days after induction of disease.
Although the area of the ventral and lateral columns were
not significantly different between the transplanted and non-
transplanted groups (P > 0.05, t test), the total number of
axons within the ventral and lateral columns of transplanted
remyelinated animals was approximately 2 the number of
axons within the ventral and lateral columns of non-trans-
planted animals (Fig. 5d). Furthermore, comparison of the
total number of axons with the number of remyelinated
axons for each animal within the transplanted group indi-
cated a statistically significant correlation between these two
values (r = 0.953). These findings suggest that a greater
degree of axonal sparing correlated with a greater degree of
remyelination. Reduced axonal loss has also been shown
after intravenous or intrathecal neurosphere transplantation
in the EAE mouse model of MS (Pluchino et al., 2003).
These data support the view that chronic demyelination is a
cause of axonal loss, and suggest that transplant-mediated
remyelination protects axons from degeneration/transection.
Further studies are required to determine the molecular
mechanisms underlying demyelination-associated axonal
degeneration/transection.
Transplantation of glial-committed progenitors resulted in
a significant improvement in locomotor abilities beginning
14 days after transplantation, which progressed to weight-
supported waddling locomotion with partial hindlimb weak-
ness (Fig. 6). Non-transplanted animals remained completely
paralyzed throughout this time period (Fig. 6). In regions of
experimental demyelination induced by lysolecithin (Smith
et al., 1979, 1981; Yezierski et al., 1992) or ethidium
bromide (Felts and Smith, 1992), return of secure axonal
conduction occurs at the same time as spontaneous remyeli-
nation and transplanted glial cells have been shown to
improve conduction velocity to near-normal values in mye-
lin-deficient rats (Utzschneider et al., 1994) and ethidium
bromide lesions (Honmou et al., 1996). Transplantation of
clonal neural cells into the intracerebroventricular system of
the shiverer mice at birth resulted in myelination of up to
52% of host neuronal processes and reduced the symptom-
atic tremor in some animals (Yandava et al., 1999). Thus, it is
intriguing that the time course of behavioral improvement
following transplantation in the current study approximates
the time required for remyelination (Pender et al., 1989;
Smith et al., 1981).
Our findings demonstrate that transplant-mediated
remyelination is possible in the complex and reactive
environment of the MHV model of multiple sclerosis.
Transplant-mediated remyelination has been demonstratedin regions of the CNS subjected to experimental demye-
lination or in myelin mutants, environments that are char-
acterized by a clear cellular deficit, a largely non-reactive
CNS environment, and a lack of inflammation. Thus,
transplantation of embryonic stem cell-derived precursors
(Brustle et al., 1999) or oligodendrocyte progenitors
(Zhang et al., 1999) into postnatal myelin-deficient rats
resulted in differentiation of transplanted cells into myeli-
nating oligodendrocytes and astrocytes. Multipotential
PSA-NCAM + neural precursors isolated from the postna-
tal rat brain have been shown to differentiate into oligo-
dendrocytes, Schwann cells, and astrocytes following
transplantation, to completely remyelinate regions of acute
demyelination in the adult rat induced by ethidium bromide
injection into x-irradiated dorsal column white matter
(Keirstead et al., 1999). Similarly, transplantation of em-
bryonic stem cells into regions of ethidium bromide in-
duced demyelination in the adult rat spinal cord or into
myelin-deficient shiverer mutant mice, resulted in the
generation of stem cell-derived oligodendrocytes that were
capable of myelinating axons (Liu et al., 2000). More
recently, transplant-mediated remyelination has been illus-
trated in the EAE model of MS, following intravenous or
intrathecal injection of adult neural precursor cells (Plu-
chino et al., 2003). Our findings confirm and extend those
outlined above, in demonstrating that intraspinal transplant-
mediated remyelination can occur in the fulminate neuro-
degenerative environment of the MHV model of MS and is
associated with locomotor improvement.
The ability of glial cell preparations to remyelinate in
such models does not necessarily indicate that their trans-
plantation into demyelinated lesions in clinical disease will
be successful (Stangel, 2002). Firstly, transplanted cells may
be subject to the same demyelinating process that led to the
development of the initial pathology. Notably, the viral
‘trigger’ of pathology in the MHV model of MS is largely
cleared by 12 days post-infection (Lane et al., 1998; Stohl-
man and Hinton, 2001), before the time of implantation in
the current study. Secondly, the inability of glial progenitors
to migrate through normal tissue (O’Leary and Blakemore,
1997) renders them less than ideal for remyelinating dispa-
rate foci of demyelination as seen in clinical disease (Prineas
et al., 1993a). Thirdly, human transplantation necessitates a
human progenitor or stem cell population that is capable of
amplification and is myelinogenic. Although robust ampli-
fication of human embryonic stem cells has been achieved
(Carpenter et al., 2001; Reubinoff et al., 2001), the con-
ditions needed to differentiate them into a remyelination-
competent transplant population have not yet been defined.
And fourthly, the gliotic environment of clinical lesions,
which may contribute to the failure of endogenous remyeli-
nation, may prohibit the transplant population from effect-
ing repair. Clearly, several key issues must be addressed
before a cellular replacement strategy can be considered for
the treatment of human demyelinating pathologies such as
MS.
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